{
  "ALL": "Acute Lymphoblastic Leukemia",
  "API": "Active Pharmaceutical Ingredient",
  "Ara-C": "cytarabine",
  "CMO": "Contract Manufacturing Organization",
  "CNS": "Central Nervous System",
  "CR": "complete remission",
  "DFS": "disease-free survival",
  "DNR": "daunorubicine",
  "DEX": "dexamethasone",
  "EFS": "event-free survival",
  "EIG": "événement indésirable grave (see SAE)",
  "G/L": "Giga /liter",
  "GMP": "Good Manufacturing Practices",
  "HD-MTX": "High-Dose Methotrexate",
  "HR": "High Risk",
  "HSCT": "Hematopoietic Stem Cell Transplantation",
  "IM": "intramuscular",
  "IMP": "Investigational Medicinal Product",
  "IT": "intrathecal injection",
  "IV": "intravenous infusion",
  "MR": "Medium Risk",
  "MRD": "minimal residual disease",
  "MTX": "methotrexate",
  "NCI": "National Cancer Institute",
  "NCI-CTCAE": "National Cancer Institute Common Terminology Criteria for Adverse Events",
  "OS": "overall survival",
  "PEG": "pegaspargase i.e. pegylated asparaginase",
  "PNN": "neutrophils",
  "PRED": "prednisone",
  "SAE": "severe adverse event",
  "6-MP": "6-mercaptopurine",
  "SR": "Standard Risk",
  "6-TG": "6-thioguanine",
  "TP": "Time Point",
  "TLP": "Traumatic Lumbar Punction",
  "VCR": "vincristine",
  "VHR": "Very High Risk",
  "WBC": "White Blood Cell Count",
  "ACR": "American College of Rheumatology",
  "EULAR": "European League Against Rheumatism",
  "AD": "Autoimmune Disease",
  "AE": "Adverse Event",
  "AHSCT": "Autologous Hematopoietic Stem Cell Transplantation",
  "BMI": "Body Mass Index",
  "CTC-AE": "NCI Common Terminology Criteria for Adverse Events",
  "CRISS": "ACR Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis",
  "DLCO": "diffusing capacity of lung for carbon monoxide",
  "EQ-5D-5L": "EuroQol 5-Dimension 5-Level",
  "FVC": "Forced Vital Capacity",
  "GRCS": "Global Rank Composite Score",
  "HRQoL": "Health-Related Quality of Life",
  "MMF": "Mycophenolate mofetil",
  "mRSS": "modified Rodnan Skin Score",
  "MSC": "Mesenchymal Stromal Cells",
  "MSC (AT)": "Mesenchymal Stromal Cells derived from AdiposeTissue",
  "MSC (M)": "Mesenchymal Stromal Cells derived from bone Marrow",
  "MSC (UC)": "Marrow derived Mesenchymal Stromal Cells derived from Umbilical Cord",
  "QALY": "Quality-Adjusted Life Year",
  "PFS": "Progression-Free Survival",
  "SAR": "Serious Adverse Reactions",
  "SHAQ": "Scleroderma-Health Assessment Questionnaire",
  "SF-36": "The Short Form (36) Health Survey",
  "SSc": "Systemic Sclerosis",
  "ADA": "Anti-drug antibodies",
  "ADCC": "Antibody dependent cell-mediated cytotoxicity",
  "ALT": "Alanine amino transferase",
  "Anti-VEGF": "Anti-vascular endothelial growth factor",
  "AST": "Aspartate amino transferase",
  "ATC": "Anatomical-Therapeutic-Chemical classification",
  "AUC": "Area under the curve",
  "AZA": "Azathioprine",
  "BCVA": "Best corrected visual acuity",
  "BRB": "Blood-retinal barrier",
  "BUN": "Blood urea nitrogen",
  "CBC": "Complete blood count",
  "CHO": "Chinese hamster ovary",
  "CINCA": "Chronic Infantile Neurological Cutaneous Articular Syndrome",
  "CRF": "Case Report Form",
  "CSA": "Cyclosporine A",
  "CTCAE": "Common Terminology Criteria for Adverse Events",
  "dL": "Deciliter",
  "EAU": "Experimental autoimmune uveitis/uveoretinitis",
  "EC": "Ethics Committee",
  "ECG": "Electrocardiogram",
  "ECL": "Electrochemiluminescence",
  "EDC": "Electronic data capture",
  "eCRF": "Electronic case report form",
  "EIU": "Endotoxin-induced uveitis",
  "EMA": "European Medicines Agency",
  "ETDRS": "Early treatment diabetic retinopathy study",
  "FFA": "Fundus Fluorescein Angiography",
  "g/day": "Grams per day",
  "g/dL": "Grams per deciliter",
  "GCP": "Good Clinical Practice",
  "GLP": "Glucagon-like peptide or Good Laboratory Practice (note context)",
  "H1N1": "Hemagglutinin type 1 and neuramimidase type 1",
  "HIV": "Human immunodeficiency virus",
  "hs-CRP": "High sensitivity C-reactive protein",
  "IC50": "Half maximal inhibitory concentration",
  "ICH": "International Conference on Harmonization",
  "ID": "Identification",
  "INH": "Isonicotinylhydrazine (also known as isoniazid)",
  "IRS": "Interactive response system",
  "IUD": "Intrauterine device",
  "IUSG": "International Uveitis Study Group",
  "KD": "Equilibrium dissociation constant",
  "kg": "Kilograms",
  "Ltd": "Limited",
  "mAb": "Monoclonal antibody",
  "MedDRA": "Medical Dictionary for Regulatory Activities",
  "mg": "Milligrams",
  "mm": "Millimeter",
  "mm3": "Cubic millimeter",
  "MPS": "Mycophenolate sodium",
  "MRI": "Magnetic Resonance Imaging",
  "NEI": "National Eye Institute",
  "nM": "Nanomolar",
  "NOAEL": "No-observed-adverse-effect-level",
  "OCT": "Optical coherence tomography",
  "OUD": "Occurrence of uveitic disease",
  "PBMC": "Peripheral blood mononuclear cell",
  "PD": "Pharmacodynamic",
  "pH": "Hydrogen ion concentration",
  "PK": "Pharmacokinetic",
  "pM": "Picomolar",
  "PO2": "Oxygen pressure",
  "PPD": "Purified protein derivative",
  "Q4W": "Every 4 weeks",
  "QOL": "Quality of life",
  "RA": "Rheumatoid arthritis",
  "rHu": "Recombinant human",
  "rMu": "Recombinant mouse",
  "SC": "Subcutaneous",
  "SPR": "Surface Plasmon Resonance",
  "SUN": "Standardization of Uveitis Nomenclature",
  "TB": "Tuberculosis",
  "TBD": "To be determined",
  "TH1": "T helper 1 cell",
  "TH17": "T helper 17 cell",
  "TLR": "Toll-like receptor",
  "TNFα": "Tumor necrosis factor alpha",
  "T2D": "Type 2 diabetes",
  "ULN": "Upper limit of normal",
  "WHODD": "World Health Organization Drug Dictionary",
  "WMA": "World Medical Association",
  "ACE2": "Angiotensin Converting Enzyme 2",
  "AGEPS": "Agence générale des équipements et produits de santé",
  "ANSM": "Agence nationale de sécurité du medicament et des produits de santé",
  "APHP": "Assistance Publique Hôpitaux de Paris",
  "ANC": "Absolute neutrophil count",
  "CNIL": "Commission nationale informatique et libertés",
  "COPD": "chronic obstructive pulmonary disease",
  "CPK": "Creatinine phosphokinase",
  "CPP": "comité de protection des personnes",
  "CRA": "Clinical Research Associates",
  "CRB": "Centre de Ressources Biologiques",
  "CRP": "C Reactive protein",
  "CRPV": "Centre Régional de Pharmacovigilance",
  "DRCI": "Délégation à la Recherche Clinique et à l’Innovation",
  "DSMB": "Data safety monitoring board",
  "DSUR": "Development Safety Update Report",
  "ECMO": "extra corporeal membrane oxygenation",
  "ER": "emergency room",
  "Gamma-GT": "gamma glutamyl transpeptidase",
  "GP": "general practitioner",
  "HCSP": "Haut Conseil à la Santé Publique",
  "ICU": "intensive care unit",
  "ITT": "intent to treat",
  "IEAC": "independent endpoint adjudication comittee",
  "NIV": "non invasive ventilation",
  "PHRC": "programme hospitalier de recherche clinique",
  "PI": "principal investigator",
  "RTPCR": "reverse-transcription polymerase chain reaction",
  "SpO2": "Peripheral oxygen saturation by pulse oxymeter",
  "RRT": "renal replacement therapy",
  "SBIM": "Service de Biostatistique et Information Médicale",
  "TMPRSS2": "cellular serine protease",
  "WHO": "World health organization",
  "ALAT": "Alanine-Aminotransferase",
  "ASAT": "Aspartate Amino Transferase",
  "AT": "Anti Thrombin",
  "ATG": "Anti ThymoGlobulin",
  "BID": "Twice a day",
  "BM": "Bone Marrow",
  "CIR": "Cumulative Incidence of Relapse",
  "CIV": "ContinuousIntravenous",
  "CML": "ChronicMyelogenous Leukemia",
  "CPM": "Cyclophosphamide",
  "CSF": "Cerebro Spinal Fluid",
  "DIVC": "Disseminated Intravascular Coagulation",
  "DMA": "Drug Marketing Authorization",
  "DVI": "Dexamethasone, Vincristine, ITK",
  "ECOG": "Eastern Cooperative Oncology Group (= PS)",
  "ET AL": "others",
  "FFD": "Form of Functions Delegation",
  "FFP": "Fresh Frozen Plasma",
  "FGM": "France Greffe de Moelle",
  "FR": "Shortening Fraction",
  "G-CSF": "Granulocyte colony-stimulating factor",
  "GNB": "Gram Negative Bacteria",
  "GPB": "Gram Positive Bacteria",
  "GVH": "Graft versus Host",
  "GVHD": "Graft versus host disease",
  "HCR": "Hematologic Complete Remission",
  "HD": "High Dose",
  "HLA": "Human Leukocyte Antigen",
  "HSC": "Hematopoietic Stem Cells",
  "ISC": "Independent Surveillance Committee",
  "IVD": "Intravenous Direct",
  "LR": "Low Risk",
  "LWH": "Low Weight Heparin",
  "MAC": "Myelo Ablative Conditioning",
  "MMolR": "Major Molecular Response",
  "NRM": "Non Relapse related Mortality",
  "NYHA": "“New York Heart Association”",
  "PO": "Per Os",
  "PS": "Performans Status (= ECOG)",
  "RBC": "Red Blood Cells",
  "RFS": "Relapse-Free Survival",
  "RTC": "Reduced Toxicity Conditioning",
  "SGOT": "Serum Glutamic OxaloaceticTransferase",
  "SGPT": "Serum GlutamopyruvateTransferase",
  "SIV": "Slow Intravenous",
  "SPC": "Summary of Product Characteristics",
  "TBI": "Total Body Irradiation",
  "TD": "Total Dose",
  "TDM": "Tomodensitometry",
  "TKI": "Tyrosine Kinase Inhibitor",
  "TUA": "Temporary Usage Authorization",
  "VDS": "Vindesine",
  "VEF": "Ventricular Ejection Fraction",
  "VP-16": "Etoposide"
}